Showing results (311-320 of 356) with videos related to
Sort By:
Pageof 36
The Lancet. Gastroenterology & Hepatology|June 27, 2017
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trialTim Meyer, Richard Fox, Yuk Ting Ma, et al.British Journal of Cancer|March 30, 2016
Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI gradeHidenori Toyoda, Paul B S Lai, James O'Beirne, et al.Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|August 19, 2018
The diagnostic value of Rosemont and Japanese diagnostic criteria for 'indeterminate', 'suggestive', 'possible' and 'early' chronic pancreatitisAndrea R G Sheel, Ryan D Baron, Ioannis Sarantitis, et al.International Journal of Cancer|November 13, 2008
TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistanceNathalie Wong, Winnie Yeo, Wai-Lap Wong, et al.Journal of the National Cancer Institute|October 20, 2005
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinomaWinnie Yeo, Tony S Mok, Benny Zee, et al.Molecular Cancer Research : MCR|January 20, 2023
BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic StratificationSarah E Barnett, Jenna Kenyani, Martina Tripari, et al.Journal of Veterinary Internal Medicine|December 7, 2018
Viral testing of 10 cases of Theiler's disease and 37 in-contact horses in the absence of equine biologic product administration: A prospective study (2014-2018)Joy E Tomlinson, Bud C Tennant, Alyssa Struzyna, et al.Liver International : Official Journal of the International Association for the Study of the Liver|October 4, 2019
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenibTim A Labeur, Sarah Berhane, Julien Edeline, et al.Diabetes, Obesity & Metabolism|September 5, 2023
No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE)Surya Panicker Rajeev, Carl Alexander Roberts, Emily Brown, et al.RMD Open|October 21, 2022
Radiological evolution of spinal disease in alkaptonuria and the effect of nitisinoneRichard Imrich, Jana Sedláková, Mária Úlehlová, et al.Pageof 36